On November 26, 2019 Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, reported that management will present at the following investor conferences (Press release, Insmed, NOV 26, 2019, View Source [SID1234551740]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Evercore ISI HealthCONx Conference in Boston on Tuesday, December 3, 2019 at 1:35 p.m. ET
The 41st NASDAQ Investor Conference in London on Wednesday, December 4, 2019 at 9:15 a.m. GMT
Each presentation will be webcast live and can be accessed by visiting the investor relations section of the company’s website at www.insmed.com. Each webcast will be archived for a period of 30 days following the conclusion of the live event.

On November 26, 2019 CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("Company"), a biotechnology company specializing in the development of novel treatments for brain tumors, reported that it has entered into a sublicense agreement with WPD Pharmaceuticals ("WPD"), a Polish corporation partially owned and controlled by Dr. Waldemar Priebe, the founder of the Company (Press release, CNS Pharmaceuticals, NOV 26, 2019, View Source [SID1234551739]). The agreement grants WPD patent rights to research and develop, and manufacture or sell Berubicin in a limited territory comprised mainly of Eastern Europe and Central Asia. The Company is entitled to a 1% royalty on all commercial sales of Berubicin in these licensed territories.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As part of the agreement, WPD committed to a $2.0 million minimum expenditure on the development, testing, regulatory approval, and commercialization of Berubicin during the three year term of the agreement, which ends in August 2021. WPD plans to implement a multicenter pediatric Phase I clinical trial to determine maximum tolerated dose, and to determine the efficacy of Berubicin in Phase IB and II clinical trials in adults. WPD also plans to conduct preclinical tests to determine the prospective use of Berubicin with temozolomide and with other compounds as anticancer drugs.

"We were extremely excited to enter into an agreement with WPD and to further explore the potential of Berubicin as an anthracycline internationally," commented CEO of CNS, John M. Climaco. "Our agreement with WPD is truly a testament to our unrelenting commitment to pursuing treatments for glioblastoma around the world."

About Berubicin
Berubicin is an anthracycline, a class of drugs among the most powerful chemotherapy drugs and effective against more types of cancer than any other class of chemotherapeutic agents. Anthracyclines are designed to damage the DNA of targeted cancer cells by interfering with the action of the topoisomerase II, a critical enzyme enabling cell proliferation. Berubicin was developed at the MD Anderson Cancer Center (MDACC), the world’s largest cancer research facility. Berubicin appeared to demonstrate one Durable Complete Response in a Phase I human clinical trial conducted by a prior developer.

On November 26, 2019 BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a Phase 3 clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu vaccine candidate, reported its financial results for the quarter ended September 30, 2019 (Press release, BiondVax Pharmaceuticals, NOV 26, 2019, View Source [SID1234551738]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Third Quarter 2019 Financial Summary

Results are in New Israel Shekels (NIS) and convenience translation to $US is provided using the exchange rate of 3.482 (NIS/$US) as at September 30, 2019.

Third quarter operating expenses were NIS 18.9m ($5.4m) compared with NIS 5.8m for the third quarter of 2018;
Third quarter R&D expenses amounted to NIS 16.1m ($4.6m) compared with NIS 4.3m for the third quarter of 2018;
Expenses were related to execution of planned ongoing operations, including the ongoing pivotal, clinical efficacy, Phase 3 trial of the Company’s M-001 Universal Flu Vaccine candidate and construction of a mid-size pilot manufacturing facility.

As of September 30, 2019, BiondVax had cash and cash equivalents of NIS 75.2 million ($21.6 million) as compared to NIS 33.9 million as of June 30, 2019.

Recent Business highlights:

$20 million was raised in a shareholder rights offering that concluded in July 2019. As a consequence of the offering and an associated option to purchase ordinary shares that were not purchased by other shareholders in the offering, Angels Investments in High Tech Ltd., wholly owned by Marius Nacht, lead investor of the aMoon Fund, held approximately 42% of outstanding BiondVax shares.
Mr. Mark Germain was appointed Chairman of BiondVax’s Board of Directors, effective September 30, 2019.
In October 2019, BiondVax received €4 million from the European Investment Bank (EIB). These funds are the final tranche of the previously announced co-financing agreement signed in June 2017 and extended in April 2019 from €20 million to €24 million.
Laboratory work for the primary and secondary outcome measures in the NIAID-sponsored Phase 2 clinical trial in the USA is now complete and the analysis is ongoing. Results are expected in Q2 2020.
Enrollment and randomization of 12,463 participants was successfully completed in the pivotal, clinical efficacy, Phase 3 trial of BiondVax’s M-001 Universal Influenza Vaccine candidate.

On November 26, 2019 BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, reported it has been invited to present at the following two investor conferences in December (Press release, Biolase Technology, NOV 26, 2019, View Source [SID1234551737]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

8th Annual Benchmark Discovery One-on-One Conference
Wednesday, December 4, 2019
The New York Athletic Club
New York City

12th Annual LD Micro Main Event
Wednesday, December 11, 2019 at 11:40 am PT (formal presentation and one-on-one meetings)
Luxe Sunset Boulevard Hotel
Los Angeles, CA

BIOLASE President and CEO Todd Norbe and Executive Vice President and CFO John Beaver will present and/or host one-on-one and small group meetings with investors at these conferences. Meetings can be scheduled through the firms hosting the conferences or through BIOLASE’s investor relations firm, EVC Group LLC (contact information below).

To access the live webcast or replay of the formal presentation at the LD Micro conference, visit the investor relations section of the company’s website at www.biolase.com.

On November 26, 2019 Ardelyx, Inc. (NASDAQ: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with cardiorenal diseases, reported that Mike Raab, president and chief executive officer of Ardelyx, will participate in a fireside chat at the Piper Jaffray 31st Annual Healthcare Conference on Tuesday, December 3, 2019 at 2:00 p.m. ET in New York City (Press release, Ardelyx, NOV 26, 2019, View Source [SID1234551734]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the live webcast of Ardelyx’s presentation please visit the Events & Presentations page within the Investor section of the Ardelyx website at ir.ardelyx.com. A replay of the webcast will be available on the Ardelyx website for 90 days following the conference.